… showed that tocilizumab treatment led to a 58% reduction in the cumulative glucocorticoid
dose in the tocilizumab group compared with the glucocorticoid monotherapy group (Table 3). …

… polymyalgia rheumatica (PMR) can be challenging. The most efficacious and cost-effective
treatment of PMR is some type of glucocorticoid … alternatives to glucocorticoid monotherapy in …

… glucocorticoid-sparing effect [Citation59]. In contrast, none of the PMR patients used as
controls, who were treated with glucocorticoids in monotherapy, reached glucocorticoid-free …

… for patients with glucocorticoid-dependent polymyalgia rheumatica. IL-… active
glucocorticoid-dependent polymyalgia rheumatica. … with glucocorticoid-dependent polymyalgia …

… Polymyalgia rheumatica (PMR) is a common inflammatory condition of elderly persons. Clinical
symptoms are improved by low-dose glucocorticoids (… of GC monotherapy until remission …

… glucocorticoids or with relapsing disease require other therapies aimed mainly to spare
glucocorticoids. … Another randomized control trial with etanercept in monotherapy versus placebo …

… we did not expect rituximab to show relevant efficacy before 11 weeks after infusion in most
patients with polymyalgia rheumatica. Therefore, we started with a regular glucocorticoid …

… for PMR, various glucocorticoid-related … , of glucocorticoids in some cases. The objective
of this study was to elucidate the efficacy of TCZ monotherapy in the absence of glucocorticoids …

… Two patients achieved remission with TCZ monotherapy (… Two patients achieved remission
with TCZ monotherapy (… TCZ as a GC-sparing agent or as monotherapy for PMR patients. The …

… glucocorticoid monotherapy is suggested, whereas in the BSR guidelines discontinuation
of glucocorticoids after 12–18 months is targeted 107,117 . The tapering of glucocorticoids can …